CSL Limited Company Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.

The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSL Limited

Country	Australia
Founded	1916
Industry	Biotechnology
Sector	Healthcare
Employees	32,698
CEO	Paul McKenzie

Contact Details

Address: 655 Elizabeth Street Melbourne, VIC 3000 Australia
Phone	61 3 9389 1911
Website	csl.com.au

Stock Details

Ticker Symbol	CSL
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	USD
ISIN Number	AU000000CSL8
SIC Code	2836

Key Executives

Name	Position
Dr. Paul F. McKenzie Ph.D.	MD, Chief Executive Officer and Executive Director
Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI	Interim Executive Vice President of CSL Behring
Andy Schmeltz	Executive Vice President of CSL Behring Business Unit (Leave of Absence)
John A. G. Levy CPA	Interim Chief Financial Officer
Chris Cooper	Head of Investor Relations
Gregory Boss B.S., BS(Hons), J.D.	Executive Vice President of Legal and General Counsel
Roanne Parry	Chief Human Resources Officer
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D.	Senior Vice President of Research
Dr. William Mezzanotte M.D., M.P.H.	Executive Vice President and Head of Research and Development
Mark Hill B.A., M.B.A.	Chief Digital Information Officer and Executive Vice President